Patent ID: 11957715
Assignee: MILTENYI BIOTEC B.V. &CO.KG
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 10:
11. A method for improving efficiency of transducing a nucleic acid into human natural killer (NK) cells; wherein the transducing comprises contacting the NK cells with a retroviral vector containing said nucleic acid, wherein the method is improved:
(a) by using a pseudotyped retroviral vector to transduce the NK cells, wherein the pseudotyped retroviral vector comprises either: (1) a chimeric envelope glycoprotein in which the transmembrane and extracellular domain of a baboon endogenous retrovirus (BaEV) envelope glycoprotein is recombinantly fused the cytoplasmic tail domain of a murine leukemia virus (MLV) envelope glycoprotein; or (2) a BaEV envelope glycoprotein that has been recombinantly modified to remove the glycoprotein's fusion inhibitory R peptide; and
(b) by activating the NK cells comprising contacting the NK cells with one or a combination of cytokines, including interleukin-2 (IL-2) and/or interleukin-15 (IL-15) 15 before they are contacted with the pseudotyped retroviral vector; thereby improving the efficiency of the transducing of the nucleic acid into the NK cells.